Banco Bilbao Vizcaya Argentaria S.A. Has $242,000 Position in Chemed Co. (NYSE:CHE)

Banco Bilbao Vizcaya Argentaria S.A. decreased its stake in Chemed Co. (NYSE:CHE) by 5.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 456 shares of the company’s stock after selling 25 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Chemed were worth $242,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Neuberger Berman Group LLC raised its holdings in Chemed by 1.2% during the 4th quarter. Neuberger Berman Group LLC now owns 501,562 shares of the company’s stock worth $265,726,000 after purchasing an additional 5,809 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Chemed by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 340,409 shares of the company’s stock valued at $180,654,000 after buying an additional 4,966 shares during the period. FMR LLC boosted its position in Chemed by 18.9% during the fourth quarter. FMR LLC now owns 283,790 shares of the company’s stock valued at $150,352,000 after acquiring an additional 45,174 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Chemed by 8.2% during the 4th quarter. JPMorgan Chase & Co. now owns 266,786 shares of the company’s stock worth $141,343,000 after acquiring an additional 20,310 shares during the period. Finally, Epoch Investment Partners Inc. raised its position in shares of Chemed by 5.1% in the 4th quarter. Epoch Investment Partners Inc. now owns 252,237 shares of the company’s stock worth $133,635,000 after acquiring an additional 12,167 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.

Chemed Stock Performance

NYSE:CHE opened at $575.58 on Wednesday. Chemed Co. has a 52 week low of $512.12 and a 52 week high of $623.61. The firm has a 50-day moving average price of $588.34 and a two-hundred day moving average price of $566.62. The firm has a market cap of $8.41 billion, a price-to-earnings ratio of 29.08, a price-to-earnings-growth ratio of 2.15 and a beta of 0.49.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported $5.63 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.04. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The business had revenue of $646.94 million for the quarter, compared to analyst estimates of $641.78 million. During the same period last year, the company posted $5.20 earnings per share. Chemed’s quarterly revenue was up 9.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Chemed Co. will post 21.43 earnings per share for the current year.

Chemed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Monday, February 24th were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend was Monday, February 24th. Chemed’s payout ratio is 9.74%.

Insider Activity

In other news, CEO Kevin J. Mcnamara sold 1,000 shares of Chemed stock in a transaction on Monday, March 31st. The stock was sold at an average price of $615.33, for a total value of $615,330.00. Following the completion of the transaction, the chief executive officer now directly owns 101,679 shares in the company, valued at approximately $62,566,139.07. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.29% of the company’s stock.

Analyst Ratings Changes

CHE has been the subject of several recent analyst reports. Royal Bank of Canada raised their target price on Chemed from $667.00 to $674.00 and gave the stock an “outperform” rating in a research note on Monday. StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research note on Friday, March 7th.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.